background: Macrophage inhibitory cytokine-1 (MIC-1) is a multifunctional cytokine produced in high amounts by placental tissue.
Introduction
Macrophage inhibitory cytokine-1 (MIC-1), also named growth differentiation factor 15 (GDF15), is a member of the transforming growth factor-b (TGF-b) superfamily and is known to be expressed at high levels in human placenta (Bootcov et al., 1997; Lawton et al., 1997; Fairlie et al., 1999) . Comparing the serum levels of MIC-1 in pregnant women with non-pregnant control patients, a 15-fold increase could be detected by 10-14 weeks of pregnancy with rising levels in later gestation (Marjono et al., 2003) . Another report demonstrated that women who subsequently miscarried or who had already miscarried exhibited significantly lower MIC-1 serum levels. As comparably low serum levels could even be detected three weeks before diagnosis of pregnancy failure, MIC-1 is thought to have a predictive role for pregnancy outcome (Tong et al., 2004) .
Immunohistochemical studies identified that MIC-1 is predominantly expressed by trophoblast cells and thus is thought to impact on placentation (Moore et al., 2000) . In vitro studies on extravillous trophoblast (EVT) cells demonstrated an inhibitory effect of MIC-1 on trophoblast viability by stimulation of apoptosis and through growth inhibition (Morrish et al., 2001) . In addition, MIC-1 is considered as a potent regulator of matrix metalloproteinases, which provides a controlled degradation of the decidual matrix and thus impacts on the invasion of trophoblast cells (Marjono et al., 2003) .
All these studies imply that MIC-1, which is widely distributed throughout pregnancy, could play a predominant regulatory role in the establishment and maintenance of pregnancy via regulation of trophoblast function.
In parallel with the rising hormonal and MIC-1 levels with the onset of pregnancy, there is a significant increase of immune cells in human decidua (Marjono et al., 2003; Gomez-Lopez et al., 2010) . Thereby, uterine natural killer cells (uNK cells) and cells of the monocyte/ macrophage lineage can be detected as predominant cell subsets (Loke and King, 1995) . A major subgroup among the latter ones comprises antigen-presenting cells (APC)-in particular, dendritic cells (DCs). Ingesting and processing harmless (self-) antigens or potentially harmful pathogens, DCs are able to transduce crucial information to the adaptive immune system via interaction with T, B and NK cells (Banchereau and Steinman, 1998) . DCs can develop an immunostimulatory or immunoinhibitory phenotype. If the circumstances of antigen adoption are appropriate, DCs can be transformed into an immunostimulatory phenotype when exposed to inflammatory or infectious signals. Processing of captured antigens by DCs is paralleled by migration of DCs to secondary lymphoid organs and a maturation process that comprises the expression of several co-stimulatory molecules. Those matured DCs (mDCs) then predominantly express co-stimulatory molecules such as CD40, CD83 and CD86 and are able to induce antigen-specific T-cell activation (Banchereau and Steinman, 1998; Steinman, 2003) . In contrast, if situated in an adequate anti-inflammatory microenvironment DCs can develop an immunoinhibitory phenotype, which is able to prevent T-cell activation (Steinman, 2003; Rutella et al., 2006) . In the absence of stimulating signals or after exposure to specific anti-inflammatory factors such as cytokines (i.e. IL-10) and hormones (progesterone, hCG, estradiol), DCs exhibit a tolerogenic phenotype and are able to secrete antiinflammatory cytokines (Bonifaz et al., 2002; Lutz and Schuler, 2002; Sato et al., 2003) . Thus, the feto-maternal micro-milieu appears to be crucial for the direction of DC maturation via a tolerogenic or immune-activating subtype.
Like female sex hormones TGF-b1 is characterized as a potent modulator of DC phenotype and function (Beagley and Gockel, 2003; Wan et al., 2008) . Thus, TGF-b1 was found to prevent the maturation of DCs by down-regulating the expression of co-stimulatory molecules (CD83, CD86) and to induce the generation of a tolerogenic subtype by activating the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase, IDO (Strobl and Knapp, 1999; Mou et al., 2004; Belladonna et al., 2008) . MIC-1 features the structural characteristics of a TGF-b superfamily cytokine and has been described as an autocrine regulator of macrophage activation. Thus, pro-inflammatory molecules (such as IL-1 and TNF-a) secreted by activated macrophages were found to induce the production of MIC-1, which in turn limited the activation of macrophages (Bootcov et al., 1997) . So far, potential effects of MIC-1 on human DC have not been elucidated. Assuming that MIC-1 might induce a micromilieu, which generates a tolergenic subtype of DCs and thus protects the semiallogenic conceptus, we initially characterized the main decidual cell populations expressing and secreting MIC-1. Subsequently, we investigated the impact of MIC-1 on DCs by analysing their migratory and proliferative activity as well as their capacity to secrete cytokines. The phenotype of MIC-1 exposed DCs was tested by studying the expression of co-stimulatory molecules. Finally, the influence of MIC-1 on T-cell stimulatory capacity of DCs and their expression of IDO was investigated.
Materials and Methods

Tissue specimens
First-trimester decidual tissue was obtained from healthy women undergoing legal therapeutic abortion of a normal pregnancy (7-8 weeks of gestation). Fragments of decidual tissue were dissected free of embryonic tissues and washed twice with phosphate-buffered saline (PBS). Subsequently, tissue samples were used either directly for cell isolation, or fixed in 4% buffered formalin or processed in routine paraffin embedding or snap-frozen in liquid nitrogen and stored at 2808C. Sections of frozen tissue samples were evaluated after routine haematoxylin-eosin and cytokeratin staining to detect samples without signs of necrosis and inflammation but containing EVT cells and corresponding tissue used for RNA and protein extraction. The institutional Ethics Committee approved all these investigations and women gave informed consent.
Immunohistochemistry
For the detection of MIC-1 positive decidual cells, immunohistochemical staining was performed as described previously (Anacker et al., 2011) . The sections were incubated with the primary polyclonal MIC-1 antibody (Sigma, Deisenhofen, Germany) diluted in 1:50 in 'antibody diluent' (DAKO, Hamburg, Germany) and followed by the EnVision/rabbit detection system (DAKO). The highly sensitive 3,3 ′ -diaminobenzidine (DAB; DAKO) was used as chromogen and hematoxiline (Mayers, Sigma) as counterstain. The slides were dehydrated through a graded line of ethanol and then embedded in Entelan (Merck, Darmstadt, Germany).
Single cell isolation
For isolation of DCs, native decidua was thoroughly washed in PBS, blood clots were completely removed and tissue were then cut into small pieces of 1 mm 3 . Those were then digested for 20 min at 378C under slight agitation in PBS with 200 U/ml hyaluronidase (Sigma), 1 mg/ml collagenase type I (Biochrom, Berlin, Germany), 0.2 mg/ml DNAse I (2500 U/mg; Sigma) and 1 mg/ml bovine serum albumin/fraction V (Sigma). The generated cell suspension was filtered through a sterile stainless steel 50 mm wire mesh and washed once in PBS. Mononuclear cells were separated by a density gradient (Leucocyte separation medium, PAA, Cö lbe, Germany). After washing twice in PBS, cells were immediately used for specific cell isolation. The resulting single cell suspension was used for subsequent positive selection of CD56 ++ CD16 2 uNK cells. In a two-step procedure, decidual (Jokhi et al., 1994) and therefore isolated using an anti c-erb B2 antibody (Mouse IgG1; Miltenyi). We found decidual stromal cells (DSC) to be highly and specifically positive for a fibroblast-specific antibody (Anti-Fibroblast MicroBeads, IgG2a; Milteny) and used this surface marker for their enrichment. Labelled cells were passed through a positive selection column by a magnetic assisted cell sorting (MACS, Miltenyi) separator. Purity of enriched cell fractions was analysed by flow cytometry and in all cases .90% of the specific cell type was detected. Cells were subsequently used for cell culture experiments or stored at 2808C to await RNA/protein isolation. Primer sequences and PCR conditions are MIC-1 forward CCCTGCAGTCCGGATACTC and MIC-1 reverse GAACAGAGCCCG GTGAAG primers (both Sigma). For PCR reactions, 2 mg of cDNA was applied. Annealing started at 608C. All PCR products were separated on 1% agarose gels and visualized using Ethidium bromide (Sigma). Intensity of Ethidum bromide luminescence was quantified using the ImageJ software (http://rsb.info.nih.gov/ij).
Polymerase chain reaction
Western blot analysis
The frozen isolated cell pellets (10 6 cells/pellet) or sliced decidual tissue were lysed in 150 ml Ripa-buffer (Invitrogen, Karlsruhe, Germany) containing proteinase inhibitors (complete, Roche, Mannheim, Germany), phosphatase inhibitors (Phosphatase Inhibitor Cocktails Set II, Calbiochem, Germany) and 2 mM DTT (dithiothreitol; Invitrogen). The mixture was incubated on ice for 30 min and remixed every 10 min. To separate the proteins from the cell debris, the mixture was then centrifuged at 14 000g for 10 min using a QIAshredder spin column (Qiagen). Afterwards, the cell lysates were diluted 1:5 in 5 × loading buffer (Fermentas), denatured at 958C for 5 min and cooled down on ice.
The solubilized proteins were isolated on a 10% polyacrilamide gel (SDS-PAGE), and then blotted onto a nitrocellulose membrane for 90 min at 10 V using a semi-dry transfer unit (Peqlab, Erlangen, Germany). After blocking with a solution of 5% non-fat milk powder in 0.05% PBS/Tween 20, target proteins were incubated for 18 h with the rabbit-anti-MIC-1 antibody (Sigma) diluted 1:500 in 2% non-fat milk and PBS/Tween or the rabbit-anti IDO antibody (Sigma) diluted 1:1000 under the same conditions. Afterwards the membranes were incubated with a horseradish peroxidise-conjugated goat-anti-rabbit antibody (KPL, Wedel, Germany) as secondary antibody diluted 1:7500 in 2% non-fat milk and PBS/Tween. Home-made enhanced chemiluminescence (ECL; Labjournal, 2007; http://www.laborjournal.de/rubric/tricks/tricks/ trick81.html) was used as substrate and luminescence was detected on an X-ray film (Fuji, Düsseldorf, Germany). For internal loading control, the analogue procedure was used for the detection of b-actin, using a mouse-anti-actin antibody (1:10 000; Abcam plc, Cambridge, UK) followed by goat-anti-mouse POD conjugate (1: 7500; KPL, Wedel, Germany) as secondary antibody. The protein bands were quantified using the Image J Program (NIH, Bethesda, USA).
ELISA
uNK cells, monocytes, EVT and DSC (10 5 each) were cultured overnight in RPMI 1640 (Biochrom) supplemented with 10% fetal calf serum (FCS: PAN, Aidenbach, Germany) and Gentamycin (20 mg/ml; Biochrom). Secretion of MIC-1 was determined using an MIC-1 specific ELISA kit (BD Biosciences, Heidelberg, Germany). To this end, 50 ml of culture supernatant was incubated per well of the 96 well ELISA-plate. Each supernatant was analysed in undiluted form as well as after diluting 1:10 and 1:100 in 'Assay diluent' included in the kit.
Blood-monocyte-derived DC preparation
Specimens were obtained from healthy male and female human donors donating thrombocytes. White blood cells were collected in the separation chambers of the Cobe Trima Leukapharesis system at the Department of Immunohematology and Transfusion Medicine, University of Wuerzburg. Cells were isolated and cultured as described by Romani et al. (1996) . After dilution with an equal volume of PBS, citrate-buffered buffy coats were distributed over a density gradient (density 1.077 g/ml, leukocyte separation medium, PAA) and centrifuged at 400g for 30 min at room temperature. Peripheral blood mononuclear cells (PBMCs) were collected from the interface, washed twice with PBS, resuspended in AIMV-Medium (Invitrogen) and incubated for 1 h at 378C with gentamycine (20 mg/ml; Biochrom) and 2% autologous plasma on plastic dishes (TPP, Trasadigen, Switzerland). To remove non-adherent cells, the dishes were thoroughly washed several times with PBS. The remaining adherent cell fraction was used for the generation of monocyte-derived DCs by culturing them with 800 U/ml purified recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF; Leukomax, Bayer, Brussels, Belgium) and 250 U/ml IL-4 (Cellgro, Freiburg, Germany) for 5 days in RPMI 1640 (Biochrom) with 10% FCS (PAN) and 20 mg/ml gentamycine (Biochrom). On Day 3, half of the volume of medium was replaced by fresh medium and IL-4/GM-CSF. Maturation of DCs was induced on day four by adding an inflammatory cocktail containing 1000 U/ml each purified recombinant human IL-1b, IL-6 and human tumour necrosis factor alpha (TNFa; all Immunotools, Friesoythe, Germany) and 10 28 mol/l prostaglandin E 2 (PGE 2 ; Calbiochem, Bad Soden, Germany) for 24 h resulting in mDC. To obtain iDCs for control purposes, an aliquot of the cells remained in culture for another 24 h in IL-4/GM-CSF medium without addition of the maturation cocktail. All cells were harvested on Day 5 for further experiments.
Incubation of DC cultures with MIC-1 or dexamethasone or TGF-b
MIC-1 or dexamethasone (Dex) or TGF-b, which were used as internal positive controls, were added at the following concentrations to the cultured cells on Day 4 in parallel with the maturation-inducing cytokines: 0.25 ng/ml MIC-1, 2.5 ng/ml MIC-1, 10 26 M Dex or 4 ng/ml TGF-b.
All factors were used in water-soluble form. MIC-1 was obtained from tebu-bio (Offenbach, Germany), Dex from Sigma-Aldrich and TGF-b from PeproTech (Hamburg, Germany). Optimal levels of MIC-1 and TGF-b for in vitro experiments were selected based on the literature (Marjono et al., 2003) . In advance, concentration-response experiments were performed (data not shown) whereby best effects were observed with the concentrations chosen. For analysis, the cells were harvested after 24 h of culture under the influence of the factors.
Migration assay
Migration of iDCs or mDCs was measured in Matrigel-coated Transwell Chambers with 8 mm pore size (Becton Dickinson, Heidelberg, Germany). Six independent sets were performed each. DCs were either cultured for the last 24 h with 2.5 ng/ml MIC-1 or incubated right from the start of culture under the influence of 2.5 ng/ml MIC-1. Untreated DCs were used as control. After culture, cells (2 × 10 5 cells) were resuspended in 500 ml of RPMI with 1% BSA (Biochrom) and placed in the upper well. The lower well was filled with 750 ml of RPMI with 10% FCS. Migration was assessed overnight. Cells reaching the lower surface of the matrigel-coated insert were fixed in Methanol and stained with Haematoxylin. Migration was quantified by carrying out cell counts on 10 randomly selected fields at ×400 magnification. Results are expressed as the number of migrated cells per high-power field.
Cell cycle assay
To detect the proliferative activity of iDCs, cells were incubated with 2.5 ng/ml MIC-1 for 24 h. Cells were then suspended in trypsin-EDTA (Biochrom) and resuspended in PBS. The cells were fixed for 60 min in an ice-cold 70% ethanol, washed with PBS and then incubated with solution containing ribonuclease (50 mg/ml, Invitrogen). The cells were then washed in PBS and stained with propidiumiodide (PI, 50 mg/ml, Sigma) for 30 min at room temperature in the dark. The PI-elicited fluorescence was measured for individual cells using a FACS-Scan flow cytometer (BD Biosciences, Heidelberg, Germany). A total of 10 6 cells for each sample was analysed and determined the proportion of cells in the growth (G) G0/G1, DNA synthesis (S) and G2/mitosis (M) phases using standard software via calculating the corresponding mean fluorescence intensity (MFI).
Analysis of cytokine secretion by cytometric bead array
To test the secretion of IL-10, IL-1b, IL-6 and IL-8 after MIC-1 exposure, culture supernatants of isolated uNK cells, CD14 + monocytes, iDCs and mDCs as described earlier were applied for cytometric bead assay according to manufacturer's instructions (Bender Med Systems, Vienna, Austria). Briefly, bead populations with distinct fluorescence intensities coated with capture antibody proteins were mixed with PE-conjugated detection antibodies and recombinant standards or test samples and then incubated to form sandwich complexes. Beads specific for IL-10, IL-1b, IL-6 and IL-8 were detected by FACScan flow cytometer (BD Biosciences). Results were analysed using the Flow Cytomix Pro software (Bender Med systems).
FACS analysis of surface markers
Flow cytometry of DCs was performed using FITC-labelled specific antibodies and the respective isotype controls: CD25 (clone: 5C3, Pharmigen, Heidelberg, Germany), CD83 (clone: HB 15a; Beckman/Coulter, Krefeld, Germany), CD86 (clone: FUN-1, Pharmigen) and HLA-DR (clone: AB3, DAKO). Briefly, samples of 2 -5 × 10 5 cells were resuspended in 50 ml PBS supplemented with 10% human immunoglobulin (Beriglobilin, Centeon). To the cell suspension 5 ml of the antibodies in question were added and incubated for 30 min at 48C (1:10 dilution). The cells were washed, resuspended in 100 ml PBS and analysed in a FACScan flow cytometer (BD Biosciences). Propidium iodide (at 10 ng/ml) was used to identify non-viable cells. A total of 10 000 viable cells per sample were evaluated for specific staining. Results were analysed using the WinMDI-software (Version 2.8, Joseph Trotter Scripps University, USA).
Mixed lymphocyte reaction
T-cells were isolated from PBMCs by incubating them for 1 h at 48C with neuraminidase (Boehringer Ingelheim, Ingelheim, Germany)-treated sheep red blood cells. Rosettes consisting of T cells were collected following a density gradient (see DC preparation) and prepared with 0.8% NH 4 Cl for lysis. Subsequently, remaining T cells were washed in PBS and resuspended in RPMI 1640/10% FCS/gentamycine. The purity of the T-cell preparations was assessed by flow cytometric analysis of CD3, CD4 and CD8 and routinely found to be around 98%. In order to achieve strong enough proliferation to allow measurement by a non-radioactive method, T cells were prepared following the 'oxidative mitogenesis' protocols as published by Hill et al. (1999) . In brief, purified T cells were incubated in 0.5 mM sodium periodide for 15 min on ice, washed in FCS followed by two washings in RPMI1640/10%FCS. To test the capacity of DCs to stimulate allogenic T cells, DCs were co-cultured in graded doses of 9000 to 111 cells per well with 9 × 10 4 allogenic sodium periodide-treated T cells for 3 days in U-bottom 96-well plates in a volume of 350 ml in RPMI1640/10%FCS/gentamycin. To determine the proliferation-index, the cultures were incubated with WST-8 cell proliferation array kit (Biozol, Eching, Germany) in a modified MTT assay for 2 h. Optical density was analysed at 450 nm using a microplate reader. For each condition 6 -8 independent assays were performed.
Data analysis
In total, five to eight independent experiments were analysed for each test system. Since the PBMC donors did not conform to a normal distribution pattern as assessed by the Shapiro-Wilk test for normality, we used the nonparametric Mann-Whitney U-test for the comparison of surface marker expression, cytokine secretion, MIC-1 secretion, proliferative and migratory activity as well as lymphocyte stimulatory capacity. Statistical analyses refer to comparisons between MIC-1 (or Dex) pretreatment and the corresponding mDC or the untreated DC sample. P-values of ,0.05 were considered as significant (Graph-Pad Software, San Diego, USA).
Results
MIC-1 is largely expressed and secreted by extravillous trophoblasts (EVT) and DSC
Immunohistochemical staining on decidua basalis revealed that MIC-1 is principally expressed by villous cytotrophoblast cells (CTB), extravillous trophoblasts (EVT) and DSC (Fig. 1) . This observation was confirmed by an investigation of the isolated cell types by PCR and western blot experiments ( Fig. 2A and B) . Herein, DSC and EVT were shown to strongly express MIC-1 both on mRNA and protein level, whereas only a weak expression could be detected in CD14+ monocytes and in uNK cells ( Fig. 2A and B) .
To clarify the expression of MIC-1 in DSC and EVT, double staining experiments were performed. Here, we detected that MIC-1 is expressed in Fibroblast-positive DSC and c-erB2 positive EVT (Supplementary data, Fig. S1 ).
Subsequently, we determined the decidual cells secreting MIC-1. To this end, isolated decidual cells (decidual tissue: n ¼ 4-5) were cultured for 48 h, and culture supernatants were analysed by ELISA.
Again, we detected that high quantities of MIC-1 were secreted by DSC and EVT (Fig. 3) , whereas only little was secreted by CD14+ monocytes and by uNK cells.
Migration of iDC is significantly increased by MIC-1
During their maturation process, DCs are known to migrate to secondary lymphoid organs. For that reason, migration assays were performed to study the impact of MIC-1 on migratory activity of iDCs and mDCs. Here we detected that MIC-1 was able to significantly increase the migratory activity of iDCs (P , 0.01), whereas no significant effect could be observed in mDCs (Fig. 4) . The stimulatory capacity of MIC-1 was particularly high when iDCs were exposed to MIC-1 for 24 h prior to the migration assay. Incubation of DCs right from the start of DC culture ('all culture') resulted in a weaker effect (n ¼ 6 each).
Proliferative activity of iDC
MIC-1 is known to impact on the proliferation of primitive haematopoetic progenitor cells (Hromas et al., 1997) . We therefore tested whether MIC-1 is able to influence the proliferative activity of iDCs.
Cell cycle analysis was performed by flow cytometry of cell cycle. Here, we observed that MIC-1 did not change the proliferation rate of iDCs in all phases of cell cycle (Mean + SEM; G0/G1: control (MFI values): 188 + 3.15; iDCs with MIC-1 190 + 3.70; G2/M: control: 351 + 1.15; iDCs with MIC-1 349 + 7.3; S: control 252.5 + 3.47; iDCs with MIC-1 249 + 1.79; n ¼ 4).
Secretion of selected pro-inflammatory or anti-inflammatory cytokines is not affected by MIC-1
The decidual micromilieu is characterized by a special composition of chemokines and cytokines. We therefore analysed secreted cytokines of isolated decidual CD14+ monocytes and uNK cells as well as of blood-derived iDCs and mDCs after incubation with two doses of MIC-1 (n ¼ 4-5). The quantity of the selected cytokines secreted differed widely between uNK or CD 14+ monocytes, iDCs and mDC but we did not observe any significant differences of IL-10, IL-6 or IL-8 secretion after the addition of MIC-1. iDCs and mDCs barely secreted IL-10, and it was not possible to interpret the effect of MIC-1 on this cytokine (data not shown). 
Expression of co-stimulatory molecules on DC is affected by MIC-1
For detection of surface marker expression, FACS analysis was performed after the culture of PBMC-dervied DCs in the presence of MIC-1 (n ¼ 6). As expected, iDC expressed low levels of HLA-DR, CD25, CD83 and CD86. After inducing maturation by the inflammatory cocktail, a slight up-regulation of HLA-DR and CD25 and a strong one of CD83 and CD86 were observed in mDCs. This up-regulation of CD25, CD83 and CD86 was reduced after MIC-1 pretreatment similar to Dex, which was acted as a control (data not shown).
MIC-1 interferes with the T-cell stimulatory capacity of DCs
The ability of DCs to act as APCs during T-cell priming was determined by mixed lymphocyte reaction (MLR) experiments (n ¼ 7). As already known, T-cell stimulatory capacity of iDCs was observed to be low in comparison with that obtained for mDC. After maturation in the presence of Dex, DCs exhibited a reduced T-cell stimulatory capacity (Fig. 5A ). This effect was also observed in the DC pre-treated with MIC-1 (Fig. 5A) . At a DC:T ratio of 1:10, which corresponds to the physiological situation, a significant reduction of the capacity of matured DCs to induce allogenic T-cell proliferation was detected at both MIC-1 concentrations. This effect observed was comparable to that of Dex-treated cells or iDCs, respectively (Fig. 5B ).
MIC-1 shows a tendency to increase the expression of the tryptophan-catabolizing enzyme IDO IDO represents a metabolic enzyme, which is known to characterize a tolerance-inducing phenotype of DC. We therefore investigated whether MIC-1 is able modulate the expression of this pivotal enzyme in DCs. Here, we observed that MIC-1 induces the up-regulation of IDO in maturing DCs. As the expression of IDO is known to be up-regulated by culturing PBMC-derived DC in the presence of prostaglandine E2 (E2), we also cultured aliquots of the iDC in the presence of 1 mM PGE2 for 24 h parallel to the maturation process (Braun et al., 2005) . As expected, this PGE2 pre-treated DC expressed IDO at high levels comparable to those of mDCs. The cytokine-induced increase of IDO expression could be slightly down-regulated by Dex. In contrast, a significant up-regulation of IDO-expression after exposure to TGF-b was observed. Like TGF-b, MIC-1 was able to increase the expression of IDO in mDCs, however not to a significant level ( Fig. 6 ; n ¼ 4).
Discussion
To date, the mechanisms that lead to the induction of tolerance against the semiallogenic fetus are not entirely resolved. However, several studies propose that a distinct composition of cytokines is essential for the establishment and maintenance of successful pregnancy. This is the first study identifying MIC-1 in decidual cells as a cytokine that can direct the induction of a tolerogenic subtype of DC. So far, MIC-1 has been reported to act as autocrine regulatory molecule on macrophage activation (Bootcov et al., 1997) . Observing a concomitant increase in MIC-1 during early pregnancy and elevated numbers of DCs in human pregnancy decidua (which feature a special macrophage subtype expressing DC-SIGN, CD14, CD68 and HLA-DR), we hypothesized that MIC-1 could impact on a successful establishment of early pregnancy by transforming DC into a tolerant-immunosuppressive phenotype.
We firstly identified the decidual cell populations expressing and secreting MIC-1. Here, we showed that uNK cells and CD 14+ monocytes barely contribute to the large amount of MIC-1 detected in gestational tissues and maternal serum. In accordance with previous studies we confirmed that the predominant expression and secretion of MIC-1 is caused by EVT and decidual stromal cells (Fairlie et al., Figure 4 MIC-1 induces migratory activity of iDC. Migration of iDCs or mDCs was measured in transwell chambers. MIC-1 (2.5 ng/ml) was able to increase the migratory activity of iDCs, while no significant effect could be observed in mDCs. The stimulatory capacity of MIC-1 was found to be highest when exposing iDC to MIC-1 for 24 h hours. Mean + SEM, n ¼ 6. Mann-Whitney U-test. (B) At a DC:T ratio of 1:10, the T-cell stimulatory capacity of the DC was significantly reduced by MIC-1 (0.25 and 2.5 ng/ml). Mean + SEM, n ¼ 7; P-values from Mann-Whitney U-test. 1999). We therefore were led to assume that the elevated amount of DCs in decidual tissue during early pregnancy in contrast to nonpregnant endometrium (Rieger et al., 2004) could be the target of the possible modulatory action of MIC-1.
To test whether this increase in DCs during early pregnancy is promoted by migration of peripheral DCs into decidual tissue, cell migration assays were performed. So far, the effects of MIC-1 on cell motility have predominantly been investigated in human prostate cancer cells. There, a promotion of cancer cell motility was observed after exposure to MIC-1 (Senapati et al., 2010) . In our study, stimulatory effects of MIC-1 on cell migration were validated by migration assays of iDCs and mDCs. We revealed that MIC-1 is able to induce the migratory activity of DC in their highly plastic immature status, while no effects could be observed in matured DC after MIC-1 exposure. This would be in line with the general observation that it is predominantly the iDCs that exhibit migratory activity when migrating to secondary lymphoid organs after stimulation (Sallusto and Lanzavecchia 1999) . To test whether this increase in iDCs in decidual tissue could be caused by an in situ proliferation of these cells within decidual tissue, we investigated the proliferative activity of iDCs after MIC-1 exposure. In contrast to migratory activity, no increase in proliferation could be observed. In previous studies MIC-1 was even found to have an inhibitory effect on primitive haematopoetic progenitor proliferation (Hromas et al., 1997) .
The decidual micromilieu is characterized by a distinct mixture of pro-and anti-inflammatory cytokines. Members of the TGF-b superfamily such as TGF-b1 are known as potent regulators for inflammatory processes (Jones et al., 2006) . Thus, TGF-b1 is known to regulate NK cells by impairing IFN-g-induced activation and inflammatory cytokine production (Rook et al., 1986) . Regarding DCs, TGF-b is implicated in the induction of a tolerogenic subtype in the in vitro differentiation (Rutella et al., 2006) . We therefore tested the effects of MIC-1 on PBMC-derived DCs, isolated uterine NK cells and isolated CD14+ monocytes. Surprisingly, we did not observe any significant differences in the cytokine secretion of IL-6, IL-8, IL-1b and IL-10 in isolated decidual uterine NK cells and CD14+ monocytes, respectively after MIC-1 incubation. We suppose that uNK cells and CD 14+ monocytes have already been exposed to very high doses of MIC-1 in vivo, which hampers a reaction to the additional stimulus given in vitro. Incubation of maturing DCs with MIC-1 also did not elicit significant changes in the production of cytokines. Only for IL-1b, we detected a slight but not significant increase in mDC and we found only low secretion for IL-10. We therefore believe that MIC-1 can act as a genuine cytokine but cannot act directly on cytokine secretion of DC (Bootcov et al., 1997) .
The phenotype of DCs is characterized by the expression of co-stimulatory molecules that are up-regulated after contact with infectious or inflammatory agents. For phenotype analysis, we generated iDC from peripheral blood monocytes and did not use the isolated decidual CD14+ monocytes, which already showed a kind of pre-activation before exposing them to maturation stimuli and thus were not really comparable to 'real' iDCs. Dex was included in all experiments as an internal positive control, because its inhibitory effect on surface marker expression of DC is well established. Matasic et al., 1999; Piemonti et al., 1999) . In contrast to previous studies investigating the effects of TGF-b family members activin A and inhibin A, here we observed that MIC-1 caused a clear reduction of the expression of co-stimulatory molecules CD25, CD83 and CD86 (Segerer et al., 2008) . Thus, MIC-1 seems to be able to generate a phenotypically immature subtype of DCs that favours the induction of tolerance.
A peculiarity of DCs is their ability to act as potent APCs during T-cell priming. As expected, Dex clearly reduced T-cell proliferation compared with mDC (Elenkov 2004; de Jong et al., 1999) . These effects were also observed when pre-incubating maturing DCs with MIC-1. Thus, MIC-1 is able to impair the function of DCs and their ability to serve as APCs during T-cell priming. In these experiments, total effects were lower for all DCs (independently from their maturation status) than observed in our previous studies (Segerer et al., 2008 (Segerer et al., , 2009 . Possibly this is due to the fact that we could not use buffy coats (no longer available due to EU prescription for blood donations) for iDC generation but had to use separation chambers of the Cobe Trima Leukapharesis, which showed a slight preactivation of the monocytes obtained (Lee et al., 2009) .
IDO is known to represent a key enzyme in the induction of immune tolerance by inhibiting T-cell activation and proliferation through tryptophan catabolism (Katz et al., 2008) . IDO-positive DCs from tumor-draining lymph nodes have been reported to be primarily associated with the induction of tolerance by activating regulatory T cells (T reg ) (Sharma et al., 2007) . In murine pregnancy, suppression of IDO by 1-methyl-tryptophan resulted in a rejection of the concepti, reflecting a critical role for this enzyme in preventing T-cell-mediated graft rejection (Munn et al., 1998) . Previous studies reported about the induction of IDO by external addition of TGF-b (Belladonna et al., 2008) . In line with this observation, we ascertained that MIC-1, in part, shares this feature of TGF-b. Addition of MIC-1 resulted in a slight up-regulation of IDO in maturing DC. Thus, we speculate that MIC-1 could Figure 6 Expression of IDO in maturing DC is slightly unregulated by MIC-1. IDO-expression was quantified after western blot analysis in comparison with actin. In comparison to iDC, mDC had a significantly higher IDO expression, which was slightly down-regulated by Dex and in tendency up-regulated by MIC-1; TGF-b increased IDO expression in cells significantly. Mean + SEM, n ¼ 5; P-values from Mann -Whitney U-test.
contribute to the creation of a tolerogenic subtype of DC by inducing IDO expression.
In contrast to TGF-b, the specific receptors activated by MIC-1 have not yet been precisely identified, and the signalling pathway is only poorly understood. To date, it is supposed that MIC-1 might work through stimulation of TGF-b receptors type I and II and intracellular Smad signal transduction protein complexes (Xu et al., 2006) . For that reason, it is very difficult to verify whether MIC-1 affects decidual immune cells directly as described already or via another TGF-b pathway, as the effects observed were comparable to those of TGF-b detected in our earlier studies (Segerer et al., 2008) . Possibly, in vitro studies with TGF-b KO-mice could elucidate this problem.
In summary, we could demonstrate the immunomodulatory role of MIC-1 on PBMC-derived-DCs here, turning them into a less-cytotoxic and more tolerance-inducing phenotype, presumably being an important mediator of tolerance induction in pregnancy. As reduced MIC-1 levels in sera of pregnant women were able to predict a failure of pregnancy (Tong et al., 2004) , it can even be speculated that a disregulated MIC-1 expression during pregnancy could have detrimental effects on pregnancy outcome.
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